NasdaqGS:CUTR

Stock Analysis Report

Executive Summary

Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide.

Snowflake

Fundamentals

Flawless balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Cutera's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.7%

CUTR

1.9%

US Medical Equipment

0.5%

US Market


1 Year Return

41.8%

CUTR

15.6%

US Medical Equipment

6.8%

US Market

Return vs Industry: CUTR exceeded the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: CUTR exceeded the US Market which returned 6.8% over the past year.


Shareholder returns

CUTRIndustryMarket
7 Day-0.7%1.9%0.5%
30 Day-4.5%-2.1%-0.8%
90 Day16.6%-0.4%-0.9%
1 Year41.8%41.8%16.6%15.6%9.2%6.8%
3 Year119.3%119.3%72.2%67.0%45.6%36.2%
5 Year181.0%181.0%125.9%100.9%63.2%45.4%

Price Volatility Vs. Market

How volatile is Cutera's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cutera undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CUTR ($29.5) is trading below our estimate of fair value ($59.36)

Significantly Below Fair Value: CUTR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CUTR is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CUTR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CUTR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CUTR is overvalued based on its PB Ratio (9.7x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Cutera forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

72.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CUTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CUTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CUTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CUTR's revenue (9.9% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: CUTR's revenue (9.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CUTR's Return on Equity is forecast to be low in 3 years time (5%).


Next Steps

Past Performance

How has Cutera performed over the past 5 years?

4.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CUTR is unprofitable, but has reduced losses over the past 5 years at a rate of 4.7% per year.

Accelerating Growth: Unable to compare CUTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CUTR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: CUTR has a negative Return on Equity (-80.58%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CUTR is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CUTR is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Cutera's financial position?


Financial Position Analysis

Short Term Liabilities: CUTR's short term assets ($88.0M) exceeds its short term liabilities ($52.9M)

Long Term Liabilities: CUTR's short term assets (88.0M) exceeds its long term liabilities (11.9M)


Debt to Equity History and Analysis

Debt Level: CUTR is debt free.

Reducing Debt: CUTR has not had any debt for past 5 years.


Balance Sheet

Inventory Level: CUTR has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CUTR's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CUTR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CUTR is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -12.5% per year.


Next Steps

Dividend

What is Cutera's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CUTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CUTR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CUTR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CUTR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CUTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cutera's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Dave Mowry (57yo)

0.3yrs

Tenure

0

Mr. David H. Mowry, also known as Dave, is the Chief Executive Officer and Director at Cutera, Inc. since July 9, 2019. Mr. Mowry served as the Director, President and Chief Executive Officer of Vyaire Me ...


Management Age and Tenure

1.7yrs

Average Tenure

53yo

Average Age

Experienced Management: CUTR's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Age and Tenure

3.0yrs

Average Tenure

64yo

Average Age

Experienced Board: CUTR's board of directors are considered experienced (3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$471,13704 Jun 19
Voce Capital Management, LLC
EntityCompany
Shares28,166
Max PriceUS$16.93
BuyUS$121,11316 May 19
Voce Capital Management, LLC
EntityCompany
Shares7,145
Max PriceUS$16.95
BuyUS$15,71125 Jan 19
Teton Advisors, Inc
EntityCompany
Shares1,000
Max PriceUS$15.73
BuyUS$542,42825 Jan 19
GAMCO Investors, Inc.
EntityCompany
Shares161,801
Max PriceUS$17.94
SellUS$6,57825 Jan 19
GAMCO Investors, Inc.
EntityCompany
Shares25,100
Max PriceUS$17.02
SellUS$4,35230 Nov 18
GAMCO Investors, Inc.
EntityCompany
Shares4,100
Max PriceUS$21.76
BuyUS$787,79630 Nov 18
GAMCO Investors, Inc.
EntityCompany
Shares153,327
Max PriceUS$21.65
SellUS$11,56101 Nov 18
GAMCO Investors, Inc.
EntityCompany
Shares9,500
Max PriceUS$23.12
BuyUS$556,50801 Nov 18
GAMCO Investors, Inc.
EntityCompany
Shares144,180
Max PriceUS$23.26

Ownership Breakdown


Management Team

  • Rajesh Madan

    Vice President of Finance

    • Tenure: 0yrs
  • Sandy Gardiner (53yo)

    Executive VP & CFO

    • Tenure: 1.8yrs
    • Compensation: US$639.25k
  • Marina Kamenakis (60yo)

    Senior Vice President of Global Marketing & Clinical Development

    • Tenure: 1.7yrs
  • Matthew Scalo

    Vice President of Investor Relations & Corporate Development

    • Tenure: 0yrs
  • Darren Alch (53yo)

    VP, General Counsel & Secretary

    • Tenure: 0yrs
  • Dave Mowry (57yo)

    CEO & Director

    • Tenure: 0.3yrs
  • Cindee Van Vleck

    Head of Human Officer

    • Tenure: 1.7yrs
  • Michael Karavitis

    Executive VP & Chief Technology Officer

    • Tenure: 2.2yrs
  • Larry Laber (48yo)

    Executive Vice President of Sales - North America

    • Tenure: 5.1yrs
    • Compensation: US$1.74m
  • R. Richey (45yo)

    President

    • Tenure: 0.5yrs
    • Compensation: US$2.81m

Board Members

  • Joe Whitters (60yo)

    Independent Director

    • Tenure: 0.7yrs
  • David Apfelberg (77yo)

    Independent Director

    • Tenure: 20.9yrs
    • Compensation: US$150.99k
  • Kay Napier Zanotti (64yo)

    Independent Director

    • Tenure: 0.7yrs
  • Greg Barrett (65yo)

    Non-Executive Director

    • Tenure: 8yrs
    • Compensation: US$173.74k
  • Tim O'Shea (66yo)

    Independent Director

    • Tenure: 15.5yrs
    • Compensation: US$161.49k
  • Dan Plants (52yo)

    Independent Chairman

    • Tenure: 3yrs
    • Compensation: US$200.99k
  • Dave Mowry (57yo)

    CEO & Director

    • Tenure: 0.3yrs

Company Information

Cutera, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cutera, Inc.
  • Ticker: CUTR
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$417.957m
  • Shares outstanding: 14.17m
  • Website: https://www.cutera.com

Number of Employees


Location

  • Cutera, Inc.
  • 3240 Bayshore Boulevard
  • Brisbane
  • California
  • 94005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CUTRNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2004
TJ9DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2004

Biography

Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser syst ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 00:00
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.